|
Intellectual Property, often abbreviated to IP, plays an extremely significant role in the generic world, but not everybody who ought to know about it really understands it. The topic includes important matters such as patent issues and data exclusivity and these two are often confused, even though there are significant differences between them. IP issues can affect generic development, registration and launch and making mistakes due to a lack of knowledge can work out very expensive. Anyone who wants to make progress in the generic world needs to ensure that they have a good understanding of the basic issues, which this half-day seminar is designed to provide. Benefits of Attending You will gain: - An opportunity to gain an understanding of how IP affects commercial aspects of the generics business
- An opportunity to gain an understanding of how IP also affects regulatory aspects of the generics business
- An understanding of patents and their extensions with examples
- Insight into the complicated issue of data exclusivity
- An explanation of the differences between patent exclusivity and data exclusivity
- A brief examination of differences between the US and European systems
- A chance to discuss the topic with fellow professionals in your field and exchange experiences.
About your masterclass leader:
 | Peter Wittner, B.Sc., is an independent consultant specialising in the commercial and legal aspects of generics with more than 30 years’ pharmaceutical experience. Before starting his own business, Peter was responsible for European generic sales at Evans Medical and later headed the European sales and marketing department of the UK generics company H.N. Norton, which subsequently became part of IVAX. He later joined the Indian generic leader Ranbaxy as Managing Director to help set up its UK business and then returned to consultancy work. Interpharm advises new market entrants on generic strategies, helps companies that are seeking to enlarge their product portfolios, provides support in business development for generic companies based outside the EU that are trying to enter the market and acts as an agent for a CRO providing biostudies to the generic industry. In addition, Peter is a regular conference speaker, often runs seminar on topics related to the generics industry and has written a number of reports on the generics industry including: - Growth Strategies in Generics
- Generics Defense Strategies
- US and European Prescription Generic Markets
as well as a report just published in January on Indian Generics and another in May entitled “Asia: Threat or Opportunity?”. Peter is also a regular contributor to the GenericsWeb newsletter “INNsight”. |
About the organisation:
Interpharm Consultancy specialises in offering support to the generic industry, particularly companies that are new to the field or based outside Europe. Peter Wittner set up the company in 1998 after leaving Ranbaxy with the intention of sharing his experience of the generic industry at both the national and international level. Interpharm has cooperated with a number of generic companies to help them work out their strategy for expansion, but also with branded companies concerned about the potential impact of generics on certain of their brands that are nearing the end of the patent protection period. Apart from giving assistance with development of growth strategies, Interpharm helps companies looking to buy in new generic products to expand their portfolio and uses its connections with the major European generic groups to introduce overseas manufacturers to potential new business partners and markets.
|
Events Home Page
